MASTERINVEST Kapitalanlage GmbH Acquires New Shares in Bio-Rad Laboratories, Inc. $BIO

MASTERINVEST Kapitalanlage GmbH bought a new position in Bio-Rad Laboratories, Inc. (NYSE:BIO) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 4,463 shares of the medical research company’s stock, valued at approximately $1,077,000.

Other hedge funds have also recently modified their holdings of the company. Cim Investment Management Inc. boosted its position in shares of Bio-Rad Laboratories by 99.6% during the second quarter. Cim Investment Management Inc. now owns 3,048 shares of the medical research company’s stock valued at $736,000 after buying an additional 1,521 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in Bio-Rad Laboratories by 115.2% during the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 76 shares during the period. WFA of San Diego LLC purchased a new stake in shares of Bio-Rad Laboratories during the 2nd quarter valued at about $222,000. Scopia Capital Management LP bought a new stake in shares of Bio-Rad Laboratories in the second quarter worth approximately $22,862,000. Finally, Man Group plc raised its holdings in shares of Bio-Rad Laboratories by 1,096.0% during the second quarter. Man Group plc now owns 80,288 shares of the medical research company’s stock valued at $19,375,000 after purchasing an additional 73,575 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Performance

NYSE:BIO opened at $308.05 on Monday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.94 and a current ratio of 5.44. The stock has a 50-day simple moving average of $315.47 and a two-hundred day simple moving average of $281.31. The firm has a market capitalization of $8.31 billion, a PE ratio of -12.67 and a beta of 1.18. Bio-Rad Laboratories, Inc. has a 52-week low of $211.43 and a 52-week high of $373.69.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Wednesday, October 29th. The medical research company reported $2.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). The company had revenue of $653.00 million for the quarter, compared to the consensus estimate of $651.30 million. Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.19%. The company’s revenue was up .5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.01 earnings per share. Analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Insider Buying and Selling at Bio-Rad Laboratories

In other news, EVP James Barry sold 700 shares of the stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $306.18, for a total value of $214,326.00. Following the completion of the sale, the executive vice president directly owned 510 shares of the company’s stock, valued at $156,151.80. This represents a 57.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 17.83% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Wall Street Zen cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, November 22nd. Wells Fargo & Company raised their price target on Bio-Rad Laboratories from $265.00 to $340.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 8th. Citigroup increased their target price on Bio-Rad Laboratories from $350.00 to $375.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Finally, Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $358.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.